

Newark Company Hopes to Change the Face of Botox

Newark-based company gets \$45M, moves forward with clinical trials

By [David J. Nicolas](#) | [Email the author](#) | June 20, 2011

Revance Therapeutics, Inc., a biopharmaceutical company located in Newark, has received \$45 million from an investment group led by Essex Woodlands Health Ventures and NovaQuest Capital as it continues its pursuit for the first topical form of botulinum toxin A.



Revance hopes to change how to administer botulinum toxin A, the key ingredient in Botox.

Instead of relying on several injections for therapeutic or cosmetic indications, Revance CEO Dan Browne said that topical applications may be more effective.

"A topical dose is intended to improve the tolerability and address the efficacy of the drug," Browne said.

Revance, founded in 2002, has no products on the market, but is scheduled to move into phase III trials with the fresh capital for its program addressing lateral canthal lines (crow's feet wrinkles) as well as continuing its ongoing research on topical applications to curb hyperhidrosis.

According to the American Academy of Dermatology, 3 percent of Americans suffer from *hyperhidrosis*, excessive sweating of the underarms, hands or feet.

Revance is located at the [Pacific Research Center](#) off Gateway Boulevard.